On Tuesday, Linda Yaccarino, former CEO of the social media platform X, was announced as the new CEO of eMed Population Health.
This Miami-based health tech company specialises in digital management of chronic diseases, focusing on GLP-1 and GIP medications, which are widely used for weight loss and diabetes care.
Her appointment marks a bold shift from tech media to digital health, signalling eMed’s ambition to expand its reach in population health.
Yaccarino’s leadership aims to revolutionise digital chronic care
Yaccarino arrives at eMed during what the company calls a “transformative moment.”
She said, “The healthcare industry has been disrupted by technology, but not yet completely transformed by it. There is an opportunity to combine technology, lifestyle, and data in a new powerful way through digital channels that impact consumers directly in ways that have never been done before.”
Her track record of leading complex digital platforms and forming game-changing partnerships is expected to accelerate eMed’s mission to deliver accessible, effective chronic care through an all-in-one digital experience.
Before eMed, Yaccarino served as CEO of X, navigating significant challenges in advertising revenue and public relations. Before that, she held prominent roles in global advertising at NBCUniversal.
Her ability to manage large-scale partnerships and steer organisations through competitive, disruptive environments is highly regarded.
eMed’s board expressed that her arrival is a unique chance to bring dynamic leadership that will expand the company’s presence with employers and government programs worldwide and enhance innovation in peptide population health management.
Digital-first platform leading the way in GLP-1 management
Founded in 2020, eMed began by providing COVID-19 diagnostics and has evolved into an end-to-end digital platform for weight loss and chronic disease medications like Wegovy and Ozempic.
The platform integrates remote diagnostics, physician-directed prescriptions, and adherence support, aiming to make sustainable chronic care more straightforward and more affordable.
eMed claims its services can reduce the cost of weight loss programs by up to 50per cent while delivering care on demand without appointments.
Analysts like Gil Luria note that Yaccarino brings essential consumer engagement experience critical for success in health technology focused on patient-centred digital care.
Her expertise in digital revenue growth aligns with eMed’s strategy to broaden its global footprint and improve healthcare outcomes through innovative technologies and partnerships.
As Linda Yaccarino steps into her new role, this move underscores how digital disruption is not only reshaping media and advertising but is poised to transform healthcare delivery platforms, merging technology and patient care in unprecedented ways.